AKT1 and melanoma: Although the role of PI3K/AKT/mTOR in melanoma progression and drug resistance is well described, the inhibitors of the PI3K/AKT/mTOR pathway have demonstrated only limited success in clinical trials, particularly when applied as a monotherapy [35,36,37].